α-Glucosidase-IN-20 (Compound 3B) is a highly effective, orally active α-glucosidase inhibitor with potent anti-diabetic properties, evidenced by an IC50 value of 3.01 μM [1].

α-Glucosidase-IN-20 (Compound 3B) at dosages of 10 and 20 mg/kg, when administered orally once daily for four weeks, demonstrates significant antidiabetic and antihyperlipidemic activities in streptozotocin-induced diabetic male Wistar albino rats (170-200 g). It effectively reduces blood glucose levels, counteracts body weight loss, and lowers serum glucose levels post-oral glucose administration (3 g/kg), with no mortality in mice at a higher dosage of 2000 mg/kg administered daily for two weeks.